Nanomedicines for the treatment of rheumatoid arthritis: State of art and potential therapeutic strategies.
10.1016/j.apsb.2021.03.013
- Author:
Qin WANG
1
;
Xianyan QIN
1
;
Jiyu FANG
2
;
Xun SUN
3
Author Information
1. Key Laboratory of Advanced Technologies of Materials, Ministry of Education and School of Materials Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China.
2. Advanced Materials Processing and Analysis Center and Department of Materials Science and Engineering, University of Central Florida, Orlando, FL 32816, USA.
3. Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu 610041, China.
- Publication Type:Review
- Keywords:
Immune tolerance;
Inflammation resolution;
Liposome;
Micelle;
Nanomedicines;
Rheumatoid arthritis;
Stimulus-responsive delivery systems;
Targeted drug delivery
- From:
Acta Pharmaceutica Sinica B
2021;11(5):1158-1174
- CountryChina
- Language:English
-
Abstract:
Increasing understanding of the pathogenesis of rheumatoid arthritis (RA) has remarkably promoted the development of effective therapeutic regimens of RA. Nevertheless, the inadequate response to current therapies in a proportion of patients, the systemic toxicity accompanied by long-term administration or distribution in non-targeted sites and the comprised efficacy caused by undesirable bioavailability, are still unsettled problems lying across the full remission of RA. So far, these existing limitations have inspired comprehensive academic researches on nanomedicines for RA treatment. A variety of versatile nanocarriers with controllable physicochemical properties, tailorable drug release pattern or active targeting ability were fabricated to enhance the drug delivery efficiency in RA treatment. This review aims to provide an up-to-date progress regarding to RA treatment using nanomedicines in the last 5 years and concisely discuss the potential application of several newly emerged therapeutic strategies such as inducing the antigen-specific tolerance, pro-resolving therapy or regulating the immunometabolism for RA treatments.
